Differential Diagnosis: Overlapping Spondyloarthritis and Hypermobility Spectrum Disorder
This patient most likely has overlapping psoriatic arthritis (PsA) with axial involvement and hypermobility spectrum disorder (HSD), with associated autonomic dysfunction (subclinical POTS) and mast cell activation syndrome (MCAS).
Primary Diagnostic Considerations
1. Psoriatic Arthritis (Axial Subtype)
The combination of HLA-B27 positivity, sacroiliac joint erosions, and psoriasiform skin changes strongly suggests axial PsA. HLA-B27-positive PsA patients demonstrate earlier disease onset, more frequent axial involvement (46.2% vs 24.5%), higher enthesitis rates (33.3% vs 18.4%), and elevated inflammatory markers compared to HLA-B27-negative patients 1. The presence of osseous erosions in the SI joints indicates established structural damage consistent with inflammatory spondyloarthritis 2.
The psoriasiform epidermal hyperplasia and hyperkeratosis represent the cutaneous manifestation of PsA, even if classic plaque psoriasis is not fully developed. HLA-B27 positivity in PsA is associated with axial disease patterns similar to ankylosing spondylitis 3, 4.
2. Hypermobility Spectrum Disorder (HSD)
The joint hypermobility with frequent subluxations points toward HSD rather than hypermobile Ehlers-Danlos syndrome (hEDS), particularly given the multisystem involvement. Patients with HSD frequently present with ADHD-type symptoms, autonomic dysfunction including POTS, and multiple chemical/food sensitivities 5, 6. The association between neurodevelopmental atypisms (ADHD symptoms) and hypermobility disorders is well-established 6.
HSD patients often report more symptoms and comorbidities than hEDS patients, including joint pain, muscle weakness, multiple sensitivities, GERD, ADHD, and heat/cold intolerance 7. This patient's presentation aligns with this pattern.
3. Mast Cell Activation Syndrome (MCAS)
The multiple chemical and food sensitivities that exacerbate symptoms, combined with hydrotic eczema, strongly suggest MCAS. There is a mechanistic link between HSD and MCAS: altered connective tissue microstructure in hypermobility disorders may trigger abnormal mast cell degranulation, leading to multisystemic symptoms 5. The skin manifestations (eczema, psoriasiform changes) can represent both PsA and MCAS overlap.
4. Postural Orthostatic Tachycardia Syndrome (POTS)
Subclinical POTS with reactive hypertension fits the autonomic dysfunction commonly seen in HSD. POTS represents impaired autonomic responses and frequently coexists with hypermobility disorders due to altered connective tissue affecting vascular compliance 5, 8.
Diagnostic Algorithm
Confirm Spondyloarthritis Diagnosis:
- Imaging: The SI joint erosions are diagnostic. Obtain MRI of sacroiliac joints and spine to assess active inflammation (bone marrow edema) versus chronic structural changes 2
- Inflammatory markers: Check CRP and ESR (expect elevation given HLA-B27 positivity) 1
- Exclude mechanical causes: Document physically demanding activities and childbirth history, as mechanical stress can mimic inflammatory findings 2
Establish Hypermobility Disorder:
- Beighton score: Assess generalized joint hypermobility
- Evaluate for hEDS vs HSD: Apply 2017 diagnostic criteria. Given the multisystem involvement without mention of skin hyperextensibility or tissue fragility, HSD is more likely than hEDS 7
Confirm MCAS:
- Serum tryptase (during and between symptomatic episodes)
- 24-hour urine histamine metabolites (N-methylhistamine)
- Document trigger patterns for foods, chemicals, temperature changes 5
Assess POTS:
- Tilt table testing or active stand test with continuous heart rate/blood pressure monitoring
- Rule out other causes of orthostatic intolerance 5
Critical Diagnostic Pitfalls
Do not dismiss the spondyloarthritis diagnosis because of joint hypermobility. These conditions can coexist, and the SI joint erosions with HLA-B27 positivity indicate true inflammatory disease, not just mechanical stress from hypermobility 2, 1.
Do not attribute all symptoms to a single diagnosis. This patient has overlapping conditions that require simultaneous management. The chemical/food sensitivities are not explained by PsA alone and point toward MCAS 5.
HLA-B27-negative spondyloarthritis exists but is less likely here. With confirmed HLA-B27 positivity and SI erosions, the diagnosis is secure. However, be aware that HLA-B27-negative patients can have peripheral-predominant disease 3, 9.
Alternative Considerations
Less Likely Diagnoses:
- Ankylosing spondylitis alone: The prominent hypermobility, skin findings, and multisystem involvement extend beyond typical AS
- Reactive arthritis: No mention of preceding infection; chronic erosive changes argue against this 3
- Undifferentiated spondyloarthritis: The psoriasiform skin changes and erosive disease support specific PsA diagnosis
Rule Out:
- Systemic lupus erythematosus: Check ANA, anti-dsDNA if clinical suspicion exists
- Inflammatory bowel disease-associated arthritis: Assess for GI symptoms beyond those explained by MCAS/HSD 5
Management Implications
Treatment must address all three primary conditions simultaneously:
- PsA management: TNF inhibitors or IL-17 inhibitors for axial disease and skin manifestations
- MCAS treatment: H1/H2 antihistamines, mast cell stabilizers, trigger avoidance 5
- POTS management: Increased fluid/salt intake, compression garments, exercise training; consider fludrocortisone or midodrine if conservative measures fail 5
- HSD supportive care: Physical therapy focusing on joint stabilization, pain management, nutritional counseling for elimination diets 5
The ADHD-type symptoms may improve with treatment of the underlying conditions, particularly MCAS and POTS, but may require independent evaluation 6.